You are a helpful, respectful, and honest assistant. Always answer as helpfully as possible, while being safe. Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content. Please ensure that your responses are socially unbiased and positive in nature. If a question does not make any sense or is not factually coherent, explain why instead of answering something not correct. If you don't know the answer to a question, please don't share false information.
What is CD4 counts should be monitored weekly during therapy with? and explain in detail?
Alefacept is an engineered protein consisting of the CD2-binding poion of leukocyte-function-associated antigen-3 (LFA-3) fused to a human IgG1 Fc region (hinge, CH1, and CH2), approved for the treatment of plaque psoriasis. It inhibits activation of T-cells by binding to cell surface CD2, inhibiting the normal CD2/LFA-3 interaction. Treatment of patients with Alefacept also results in a dose-dependent reduction of the total number of circulating T cells, including those that predominate in psoriatic plaques. Therefore, T-cell counts of patients receiving Alefacept must be monitored, and the drug discontinued if CD4 lymphocyte levels fall below 250 cells/ L.